ALTHEOME

What this means for you

Not registered yet, but its 06 Jan 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79451635

Mark type

Stylized text

Filed

06 Jan 2026

Goods and services

• Class 042 — Scientific and technological services: Biotechnological research services; scientific research services; laboratory research services; laboratory testing services; design and product development services; scientific analysis services; biological research services; medical research services; research and development services; clinical trials; DNA sequencing for medical research and technology research purposes; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinical trials, and DNA sequencing for medical research and technology research purposes, all the aforesaid services relating to proteomics, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinical trials, and DNA sequencing for medical research and technology research purposes, all the aforesaid services relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinical trials, and DNA sequencing for medical research and technology research purposes, all the aforesaid services relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; design and development of diagnostic assays, devices, and platforms; research in the field of bioinformatics; research in the field of biostatistics; computerised data storage and database design services relating to bioinformatics and biostatistics; data and database services, namely design and development of computer database software for use in data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases; computer modelling and computer simulation services; cloud computing services; design and development artificial intelligence and machine learning models; biological services, computer science services, and data analytics services, namely research in the field of bioinformatics, research in the field of biostatistics, data and database services, namely design and development of computer database software for use in data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all the aforementioned services relating to proteomics, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; biological services, computer science services, and data analytics services, namely research in the field of bioinformatic, research in the field of biostatistics, data and database services, namely design and development of computer database software for use in data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all the aforementioned services relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; biological services, computer science services, and data analytics services, namely research in the field of bioinformatics, research in the field of biostatistics, data and database services, namely design and development of computer database software for use in data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all the aforesaid services relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; information, advisory and consultancy services relating to the aforesaid.
• Class 044 — Medical, beauty and agricultural services: Pathological testing for diagnostic and treatment purposes; medical testing and analysis services relating to the diagnosis and treatment of disease; laboratory analysis services relating to the diagnosis and treatment of persons; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating to the diagnosis and treatment of disease, and laboratory analysis services relating to the diagnosis and treatment of persons, all relating to proteomics, proteomics profiling services, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating to the diagnosis and treatment of disease, and laboratory analysis services relating to the diagnosis and treatment of persons, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; medical services; medical testing services; medical diagnostic services; medical analysis services; medical screening services; medical services, medical testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to proteomics, proteomics profiling services, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; medical services, medical testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; medical services, medical testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; information, advisory and consultancy services relating to the aforesaid.

Owner

• Altheome Limited, GB

Prosecution history

• 25 Aug 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 25 Aug 2026 — REFUSAL PROCESSED BY MPU
• 17 Jun 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 16 Jun 2026 — NON-FINAL ACTION WRITTEN
• 13 Jun 2026 — ASSIGNED TO EXAMINER
• 12 Jun 2026 — APPLICATION FILING RECEIPT MAILED
• 12 Jun 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 11 Jun 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB